Jonathan F. Anker

1.7k total citations · 1 hit paper
31 papers, 1.1k citations indexed

About

Jonathan F. Anker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Jonathan F. Anker has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Jonathan F. Anker's work include Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Cancer Genomics and Diagnostics (6 papers). Jonathan F. Anker is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Cancer Genomics and Diagnostics (6 papers). Jonathan F. Anker collaborates with scholars based in United States, South Korea and Japan. Jonathan F. Anker's co-authors include Young Kwang Chae, Sarki A. Abdulkadir, Francis J. Giles, Sarita Agte, Wade T. Iams, Hanlin Mok, Kenji Unno, Marcelo Cruz, Rajita Vatapalli and Barbara Lysy and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Cell.

In The Last Decade

Jonathan F. Anker

30 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

2019 302 citations Huiying Han, Atul D. Jain et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan F. Anker United States	14	617	519	251	233	227	31	1.1k
Miriam Redrado Spain	20	544 0.9×	518 1.0×	270 1.1×	233 1.0×	177 0.8×	39	1.1k
Fabiana Conciatori Italy	17	743 1.2×	463 0.9×	309 1.2×	184 0.8×	179 0.8×	23	1.2k
Johanna Tuomela Finland	19	537 0.9×	327 0.6×	179 0.7×	188 0.8×	174 0.8×	49	984
Masayuki Hiraki Japan	17	825 1.3×	464 0.9×	403 1.6×	228 1.0×	271 1.2×	58	1.3k
Stacey M. Bagby United States	21	568 0.9×	516 1.0×	242 1.0×	194 0.8×	158 0.7×	62	1.1k
Ti Wen China	24	638 1.0×	521 1.0×	319 1.3×	391 1.7×	146 0.6×	48	1.2k
Ashujit Tagde United States	17	859 1.4×	432 0.8×	292 1.2×	284 1.2×	218 1.0×	23	1.2k
Ren Zhao China	21	642 1.0×	529 1.0×	344 1.4×	260 1.1×	192 0.8×	56	1.3k
Lin Feng China	23	560 0.9×	399 0.8×	401 1.6×	313 1.3×	328 1.4×	76	1.2k
Baochi Ou China	17	602 1.0×	403 0.8×	302 1.2×	224 1.0×	118 0.5×	26	1.1k

Countries citing papers authored by Jonathan F. Anker

Since Specialization

Citations

This map shows the geographic impact of Jonathan F. Anker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan F. Anker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan F. Anker more than expected).

Fields of papers citing papers by Jonathan F. Anker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan F. Anker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan F. Anker. The network helps show where Jonathan F. Anker may publish in the future.

Co-authorship network of co-authors of Jonathan F. Anker

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan F. Anker. A scholar is included among the top collaborators of Jonathan F. Anker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan F. Anker. Jonathan F. Anker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saxena, Mansi, Jonathan F. Anker, Julia Kodysh, et al.. (2025). Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial. Nature Cancer. 6(6). 988–999. 2 indexed citations

Anker, Jonathan F., et al.. (2024). Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient. American Society of Clinical Oncology Educational Book. 44(3). e432054–e432054. 4 indexed citations

Anker, Jonathan F., Sumanta K. Pal, Seunghee Kim‐Schulze, et al.. (2023). Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer. Journal for ImmunoTherapy of Cancer. 11(8). e007613–e007613. 7 indexed citations

Anker, Jonathan F., et al.. (2021). From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells. 10(11). 3231–3231. 15 indexed citations

Oh, Michael S., Jonathan F. Anker, & Young Kwang Chae. (2021). High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC. Cancer Treatment and Research Communications. 27. 100317–100317. 11 indexed citations

Chae, Young Kwang, Andrew A. Davis, Lee Chun Park, et al.. (2020). Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy. Translational Lung Cancer Research. 9(4). 1015–1028. 15 indexed citations

Vatapalli, Rajita, Vinay Sagar, Yara Rodríguez, et al.. (2020). Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature Communications. 11(1). 4153–4153. 77 indexed citations

Chae, Young Kwang, Jonathan F. Anker, Michael S. Oh, et al.. (2019). Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. Scientific Reports. 9(1). 3235–3235. 55 indexed citations

Sagar, Vinay, Rajita Vatapalli, Barbara Lysy, et al.. (2019). EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death and Disease. 10(11). 801–801. 44 indexed citations

10.

Han, Huiying, Atul D. Jain, Mihai I. Truica, et al.. (2019). Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 36(5). 483–497.e15. 302 indexed citations breakdown →

11.

Anker, Jonathan F., et al.. (2018). Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nature Communications. 9(1). 1591–1591. 80 indexed citations

12.

Chae, Young Kwang, Jonathan F. Anker, Sarita Agte, et al.. (2018). Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Scientific Reports. 8(1). 2918–2918. 198 indexed citations

13.

Chang, Stephen, Kunsoo Rhee, Jonathan F. Anker, et al.. (2018). P1.04-01 Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC. Journal of Thoracic Oncology. 13(10). S525–S525. 2 indexed citations

14.

Murphy, Stephen F., et al.. (2018). Role of gram‐positive bacteria in chronic pelvic pain syndrome (CPPS). The Prostate. 79(2). 160–167. 9 indexed citations

15.

Anker, Jonathan F., et al.. (2018). A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. Journal of Visualized Experiments. 7 indexed citations

16.

Park, Lee Chun, Jonathan F. Anker, Michael S. Oh, et al.. (2018). Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). 12050–12050. 18 indexed citations

17.

Chae, Young Kwang, Jonathan F. Anker, Young Suk Kim, et al.. (2017). Abstract 5935: Higher tumor mutation burden (TMB) is associated with the presence of DNA repair gene mutations, T-cell infiltration, and favorable survival outcome in ovarian carcinoma. Cancer Research. 77(13_Supplement). 5935–5935. 2 indexed citations

18.

Chae, Young Kwang, et al.. (2017). Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. Cancer Treatment Reviews. 63. 116–121. 32 indexed citations

19.

Chae, Young Kwang, et al.. (2017). Association of activated B-cell infiltration in the tumor microenvironment with regulatory T-cell (Treg) infiltration, but not macrophages polarization in immunogenic human cancers.. Journal of Clinical Oncology. 35(15_suppl). e23174–e23174. 2 indexed citations

20.

Unno, Kenji, Jonathan C. Zhao, Jonathan F. Anker, et al.. (2017). Organoids model distinct Vitamin E effects at different stages of prostate cancer evolution. Scientific Reports. 7(1). 16285–16285. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact